BridgeMD
New treatment option for Influenza
Official title Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting
ClinicalTrials.gov ID: NCT07236814
What this study is testing
What is Suraxavir marboxil?
Suraxavir marboxil is an investigational medicine, being studied as a potential treatment for influenza.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to evaluate the efficacy of antiviral prophylaxis in preventing in-hospital influenza transmission. We will enroll hospitalized patients with confirmed influenza (index cases) and their uninfected roommates (room contacts).
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 and older
You may be able to join if
- (1)for Index Cases: ① Patients hospitalized at a participating medical institution.
- The subject and/or their legal guardian agrees to participate in this clinical study, has signed the informed consent form, and is able to comply...
- Age ≥ 2 years.
- Positive for influenza virus as determined by a Rapid Antigen Test (RAT) or Nucleic Acid Amplification Test (NAAT) on a respiratory specimen (e.g...
- The subject and/or their legal guardian agrees to participate in this clinical study, has signed the informed consent form, and is able to comply...
You likely can't join if
- (1) Index Cases There are no exclusion criteria for index cases. (2) Exclusion Criteria for Room Contacts:
- Room contacts with a known allergy to the active ingredients or excipients of the investigational drugs.
- Room contacts who have been diagnosed with or have had an influenza virus infection in the past 12 weeks.
- Use of any anti-influenza antiviral drugs within 2 weeks prior to screening, including: neuraminidase inhibitors, polymerase inhibitors...
- Known to be pregnant or breastfeeding. (people who suspect they may be pregnant must report this to the investigator, who will confirm with a...
- History of fever (axillary temperature ≥ 37.3°C) within 72 hours prior to screening.
See the full eligibility criteria
- (1)for Index Cases: ① Patients hospitalized at a participating medical institution.
- The subject and/or their legal guardian agrees to participate in this clinical study, has signed the informed consent form, and is able to comply with the protocol requirements for follow-up and complete all study...
- Age ≥ 2 years.
- Positive for influenza virus as determined by a Rapid Antigen Test (RAT) or Nucleic Acid Amplification Test (NAAT) on a respiratory specimen (e.g., oropharyngeal swab, nasopharyngeal swab, sputum, or bronchoalveolar...
- The subject and/or their legal guardian agrees to participate in this clinical study, has signed the informed consent form, and is able to comply with the protocol requirements for follow-up and complete all study...
- Expected to remain hospitalized for ≥ 72 hours.
- Shares a room with at least one hospitalized index case who has been confirmed with influenza virus infection by RAT or NAAT on a respiratory specimen within the last 120 hours and developed influenza-related symptoms...
- (1) Index Cases There are no exclusion criteria for index cases. (2) Exclusion Criteria for Room Contacts:
- Room contacts with a known allergy to the active ingredients or excipients of the investigational drugs.
- Room contacts who have been diagnosed with or have had an influenza virus infection in the past 12 weeks.
- Use of any anti-influenza antiviral drugs within 2 weeks prior to screening, including: neuraminidase inhibitors, polymerase inhibitors, hemagglutinin inhibitors, and M2 ion channel blockers (e.g., Oseltamivir...
- Known to be pregnant or breastfeeding. (people who suspect they may be pregnant must report this to the investigator, who will confirm with a pregnancy test).
- History of fever (axillary temperature ≥ 37.3°C) within 72 hours prior to screening.
- Child-Pugh class B or C, or an eGFR ≤ 60 mL min-¹ (1.73 m²)-¹. ⑦ Any subject deemed unsuitable for participation in the study by the investigator.
The study team makes the final eligibility decision.
Where it's taking place
- Beijing, Beijing Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beijing, Beijing Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.